Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A Yahoo Finance analysis says the market is not pricing Eli Lilly at the very top end of its peer set, even though the company is viewed as among the group’s faster growers. The gap, the post argues, reflects how investors set multiples based on expectations and uncertainty rather than growth alone.
THE APEX TIMES
THE APEX TIMES
Two shareholder groups filed a lawsuit alleging UnitedHealth misled investors and ignored internal governance and cybersecurity risks for years, culminating in failures tied to the Change Healthcare cyberattack and other oversight lapses.
THE APEX TIMES
A market commentary points to an updated Discounted Cash Flow view that, even after a steep run, implies Eli Lilly’s shares could still be trading below an estimated intrinsic value.
THE APEX TIMES
Eli Lilly says its weight-loss pill Foundayo won UK approval on August 10, becoming the first European country to clear the medicine for both weight management and type 2 diabetes, edging the company ahead of Novo Nordisk in at least one market. Novo Nordisk still holds a lead in broader European availability.
THE APEX TIMES
A fresh Yahoo Finance look at Wall Street commentary points to a favorable average brokerage recommendation for UnitedHealth (UNH). Still, the same article questions whether the widely watched recommendation averages reliably translate into better outcomes for investors.
THE APEX TIMES
A recent commentary tied behavioral health to cardiovascular outcomes, underscoring how depression, anxiety and chronic stress may affect risk and recovery in patients.
THE APEX TIMES
Even after a regulatory step forward for Moderna’s mRNA flu shot, executives and investors will likely focus on whether strain timing and broader skepticism about mRNA vaccines limit uptake.
THE APEX TIMES
A new industry outlook argues that a recovery in the drug sector could renew attention on major innovators, even as pricing pressure and patent expirations remain key risks.
THE APEX TIMES
The small-cap discovery technology company OmniAb said it has entered a global collaboration and licensing arrangement tied to an ion channel therapeutic program with Eli Lilly (LLY). Details on economics and timelines were not provided in the announcement cited by the market news post.
